IL1B and systemic-onset juvenile idiopathic arthritis: As IL-1 and IL-6 have been shown to play a primary role in the pathogenesis of SJIA, anti-IL-1 treatments as well as anti-IL-6 drugs represent promising therapeutic strategies for the control of this disease [7,9].